#South Korea #Seoul #VIVOZON #UNAFRA Inj. #Opiranserin

VIVOZON Pharmaceutical Launches UNAFRA Inj.: A Breakthrough in Pain Management

VIVOZON Pharmaceutical has recently announced a significant milestone in pain management with the approval of their revolutionary non-opioid analgesic, UNAFRA Inj., by the Ministry of Food and Drug Safety (MFDS) on December 12, 2024. This innovative drug introduces an alternative solution for individuals suffering from moderate to severe pain, marking a pivotal moment in the healthcare landscape of Korea.

A New Era in Pain Relief

Within the realm of medical advancements, UNAFRA Inj. stands out as the world’s first non-opioid analgesic that does not rely on non-steroidal anti-inflammatory drugs (NSAIDs). This groundbreaking medication is based on the active ingredient, Opiranserin HCl, and was developed using VIVOZON’s proprietary multi-target drug development platform. By simultaneously inhibiting both the glycine transporter 2 (GlyT2) and the serotonin receptor 2a (5HT2a), UNAFRA Inj. effectively blocks pain signals and reduces pain transmission in both the central and peripheral nervous systems.

The national Phase 3 clinical trial conducted prior to receiving approval confirmed the safety and tolerability of UNAFRA Inj., showcasing promising efficacy. The primary endpoint, measured by the Sum of Pain Intensity Difference over 12 hours (SPID 12), demonstrated significant statistical improvements, alongside secondary endpoints highlighting reductions in patient-controlled analgesia requests and opioid consumption over the same timeframe.

Addressing Unmet Medical Needs

The approval of UNAFRA Inj. addresses a critical gap in pain management options, providing a solution in a market that previously lacked effective alternatives to opioid analgesics. Medical professionals commend this new medication as a game-changer, noting that it alleviates pain with fewer side effects and eliminates the risk of addiction associated with traditional opioid medications, which can often lead to substantial dependency issues.

Unlike existing products that are labeled as “Best-in-Class” or “Me-Too” drugs imitating current treatments, UNAFRA Inj. is being hailed as a “First-in-Class” medication, showcasing significant advancements in drug development complexity and originality. This distinction underlines VIVOZON’s commitment to innovation within the pharmaceutical industry, solidifying its reputation as a frontrunner in the development of groundbreaking healthcare solutions.

CEO of VIVOZON Pharmaceutical expressed enthusiasm about the approval, stating, "We are thrilled to share this revolutionary news with our investors and stakeholders who have supported us throughout our journey. This approval not only paves the way for accelerating our product launch initiatives but also enhances our marketing efforts to bring our innovative solutions to the market swiftly."

Looking Ahead

As VIVOZON Pharmaceutical prepares for the introduction of UNAFRA Inj. into the healthcare market, the implications of this approval resonate far beyond South Korea. The company aims to leverage this innovation to transform pain management strategies and elevate the quality of care provided to patients worldwide. In a landscape where pain management options are desperately needed, UNAFRA Inj. could represent hope and relief for many who suffer from chronic pain conditions. As we look to the future, VIVOZON’s dedication to redefining treatment possibilities shines brightly, promising advancements in the world of pain management and drug development.

In conclusion, the approval of UNAFRA Inj. marks a transformative leap in the field of analgesics, compelling healthcare professionals and patients alike to reconsider their approach to pain treatment. VIVOZON Pharmaceutical’s commitment to innovation not only enriches the medical community but also brings hope to patients searching for effective and safer alternatives in pain management.